These results, combined with the superior therapeutic efficacy demonstrated in the previous sections, highlight the potential of TF-Cur-Nio as a safe and effective treatment option for gliomas, paving the way for its further development in clinical applications. The gene discussed is TF; the disease is central nervous system cancer.